Clinical trials update from the heart failure society of America and the American heart association meetings in 2008: SADHART-CHF, COMPARE, MOMENTUM, thyroid hormone analogue study, HF-ACTION, I-PRESERVE, β-interferon study, BACH, and ATHENA

European Journal of Heart Failure

Volumn 11, Issue 2, 2009, Pages 214-219

  Coletta, Alison P ^a   Clark, Andrew L ^a   Cleland, John G F ^a  

^a UNIVERSITY OF HULL   (United Kingdom)

Author keywords

Heart failure; Randomized controlled trials

Indexed keywords

3,5 DIIODOTHYROPROPIONIC ACID; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; AMIODARONE; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DRONEDARONE; ESCITALOPRAM; INTERFERON BETA SERINE; IRBESARTAN; LOOP DIURETIC AGENT; PLACEBO; PROADRENOMEDULLIN; SERTRALINE; THYROID HORMONE DERIVATIVE; UNCLASSIFIED DRUG;

ACUTE HEART FAILURE; AORTA FLOW; ARTICLE; CACHEXIA; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONGESTIVE CARDIOMYOPATHY; CONTROLLED CLINICAL TRIAL; CONTROLLED RELEASE FORMULATION; DEPRESSION; DISEASE SEVERITY; DOSAGE SCHEDULE COMPARISON; DRUG DOSAGE FORM COMPARISON; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; HEART ASSIST DEVICE; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART FAILURE; HEART HEMODYNAMICS; HEART LEFT VENTRICLE EJECTION FRACTION; HORMONAL THERAPY; HOSPITALIZATION; HUMAN; KINESIOTHERAPY; MAJOR DEPRESSION; MEDICAL SOCIETY; METABOLIC RATE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SIDE EFFECT; SINUS RHYTHM; STROKE; UNSPECIFIED SIDE EFFECT; VIRUS MYOCARDITIS; WEIGHT REDUCTION; CONFERENCE PAPER;

HEART FAILURE; HUMANS;

EID: 64549102113     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1093/eurjhf/hfn047     Document Type: Article

References (26)

1. Rutledge T, Reis VA, Linke SE, Greenberg BH, Mills PJ. Depression in heart failure a meta-analytic review of prevalence, intervention effects and associations with clinical outcome. J Am Coll Cardiol 2006;48:1527-1537.
2. Jiang W, Kuchibhatia M, Clary GL, Cuffe MS, Christopher EJ, Alexander JD, Califf RM, Krishnan RR, O'Connor C. Relationship between depressive symptoms and long-term mortality in patients with heart failure. Am HeartJ 2007;154: 102-108.
3. Macchia A, Monte S, Pellegrini F, Romero M, D'Ettorre A, Tavazzi L, Tognoni G, Maggioni AP. Depression worsens outcomes in elderly patients with heart failure: an analysis of 48,117 patients in a community setting. Eur J Heart Fail 2008;10: 714-721.
4. Glassmann AH, O'Connor C, Califf RM, Swedberg K, Schwartz P, Bigger JT, Krishnan KRR, van Zyl LT, Swenson JR, Finkel MS, Landau C, Shapiro PA, Pepine CJ, Mardekian J, Harrison WM, for the sertraline antidepressant heart attack randomised trial (SADHART) group. Sertraline treatment of major depression in patients with acute MI or unstable angina. J Am Med Assoc 2002; 288:701 -709.
5. Jiang W, O'Connor C, Silva SG, Kuchibhatla M, Cuffe MS, Callwood DD, Zakhary B, Henke E, Arias RM, Krishnan R, for the SADHART-CHF Investigators. Safety and efficacy of sertraline for depression in patients with CHF (SADHART-CHF): a randomized, double-blind, placebo controlled trial of sertraline for major depression with congestive heart failure. Am HeartJ 2008;156: 437-444.
6. Angermann CE, Gelbrich G, Stork S, Fallgatter A, Deckert J, Faller H, Ertl G, MOOD-HF Investigators. Rationale and design of a randomised, controlled, multi-center trial investigating the effects of selective serotonin re-uptake inhibition on morbidity, mortality and mood in depressed heart failure patients (MOOD-HF). EurJ Heart Fail 2007;9:1212-1222.
7. Greenberg BH, Mehra M, Teerlink JR, Ordronneau P, McCollum D, Gilbert EM. COMPARE: comparison of the effects of carvedilol CR carvedilol IR on left ventricular ejection fraction in patients with heart failure. Am J Cardiol 2006;98: 53L-59L.
8. Cleland JGF, Pennell DJ, Ray SG, Coats AJ, Macfarlane PW, Murray GD, Mule JD, Vered Z, Lahiri A, Carvedilol hibernating reversible ischaemia trial: marker of success investigators. Myocardial viability as a determinant of the ejection fraction response to carvedilol in patients with heart failure (CHRISTMAS trial): randomised controlled trial. Lancet 2003;362:14-21.
9. Cleland JGF, Coletta AP, Yassin A, Hado H, Cullington D, Abdellah AT, Clark AL. Clinical trials update from the American College of Cardiology 2008: CARISMA, TRENDS, meta-analysis of cyclo-oxygenase-2 data, HAT, studies related to hypertension, MOMENTUM, PROTECT, HORIZON-HF and REVERSE. EurJ Heart Fail 2008;10:614-620.
10. Greenberg B, Czerska B, Delgado RM, Bourge R, Zile MR, Silver M, Klapholz M, Haesslein E, Mehra MR, Mather P, Abraham WT, NeatonJD, Brown BS, Parker IC, Konstam MA, MOMENTUM Investigators Coordinators. Effects of continuous aortic flow augmentation in patients with exacerbation of heart failure inadequately responsive to medical therapy: results of the Multicenter Trial of the Orqis Medical Cancion System for the Enhanced treatment of Heart Failure unresponsive to Medical Therapy (MOMENTUM). Circulation 2008;118:1241-1249.
11. Cleland J, Tavazzi L, Daubert JC, Tageldien A, Freemantle N. Cardiac Resynchro-nisation Therapy. Are modern myths preventing appropriate use? J Am Coll Cardiol. (in press).
12. Pingitore A, Galli E, Barison A, Iervasi A, Scarlattini M, Nucci D, L'abbate A, Mariotti R, Iervasi G. Acute effects of triiodothyronine (T3) replacement therapy in patients with chronic heart failure and low-T3 syndrome: a randomised, placebo controlled study. J Clin Endocrinol Metab 2008;93:1351-1358.
13. Lu X, Huang J, Zhang X, Li X, Wang C, Zhang P, Chen Y. Effects of thyroxine on cardiac function and lymphocyte beta-adrenoceptors in patients with chronic congestive heart failure. Chin MedJ 2003;116:1697-1700.
14. Morkin E, Pennock GD, Spooner PH, BahlJJ, Goldman S. Clinical and experimental studies on the use of 3,5-diiodothyropropionic acid, a thyroid hormone analogue, in heart failure. Thyroid 2002;12:527-533.
15. Moruzzi P, Doria E, Agostoni PG, Capacchione V, Sganzerla P. Usefulness of L-thyroxine to improve cardiac and exercise performance in idiopathic dilated cardiomyopathy. AmJ Cardiol 1994;73:374-378.
16. Smart N, Marwick TH. Exercise training for patients with heart failure: a systematic review of factors that improve mortality and morbidity. Am J Med 2004;116: 693-706.
17. Piepoli MF, Davos C, Francis DP, Coats AJ. Exercise training meta-analysis of trials of patients with chronic heart failure (ExTra-MATCH). Br MedJ 2004;328:189.
18. Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-Wilson PA, Stromberg A, van Veldhuisen DJ, Atar D, Hoes AW, Keren A, Mebazaa A, Nieminen M, Priori SG, Swedberg K. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008 The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). EurJ Heart Fail 2008;10:933-989.
19. Whellan DJ, O'Connor CM, Lee KL, Keteyian SJ, Cooper LS, Ellis SJ, Leifer ES, Kraus WE, Kitzman DW, Blumenthal JA, Rendall DS, Houston-Miller N, Fleg JL, Schulman KA, Pina IL, HF-ACTION trial investigators. Heart failure and a controlled trial investigating outcomes of exercise training (HF-ACTION) design and rationale. Am Heart J 2007;153:201-211.
20. McKelvie RS, Teo KK, Roberts R, McCartney N, Humen D, Montague T, Hendrican K, Yusuf S. Effects of exercise training in patients with heart failure: the exercise training rehabilitation trial (EXERT). Am HeartJ 2002;144: 23-30.
21. McMurray JJV, Carson PE, Komajda M, McKelvie R, Zile MR, Ptaszynska A, Staiger C, Donovan JM, Massie BM. Heart failure with preserved ejection fraction: clinical characteristics of 4133 patients enrolled in the I-PRESERVE trial. Eur J Heart Fail 2008;10:149-156.
22. Massie BM, Carson PE, McMurray JJV, Komajda M, McKelvie R, Zile MR, Anderson S, Donovan M, Iverson E, Staiger C, Ptaszynska A, I-PRESERVE Investigators. Irbesartan in patients with heart failure and preserved ejection fraction. N EngJ Med 2008;358:2456-2467.
23. Coletta AP, Cullington D, Clark AL, Cleland JGF. Clinical trials update from European Society of Cardiology Meeting 2008: TIME-CHF, BACH, BEAUTIFUL, GISSI-HF and HOME-HF. EurJ Heart Fail 2008;10:1264-1267.
24. Coletta AP, Cleland JGF, Cullington D, Clark AL. Clinical trials update from Heart Rhythm 2008 and Heart Failure 2008: ATHENA, URGENT, INH study, HEART and CK-1827452. EurJ Heart Fail 2008;10:917-920.
25. Tschuppert Y, Buclin T, Rothuizen LE, Decosterd LA, Galleyrand J, Gaud C, BiollazJ. Effect of dronedarone on renal function in healthy subjects. Br J Clin Pharmacol 2007;64:785-791.
26. Kober L, Torp-Pedersen C, McMurray JJ, Gotzsche O, Levy S, Crijns H, Amile J, Carlsen J, Dronedarone Study Group. Increased mortality after dronedarone therapy for severe heart failure. N Eng J Med 2008;358:2678-2687.